Literature DB >> 7488817

Porcine surfactant replacement therapy in newborns of 25-31 weeks' gestation: a randomized, multicentre trial of prophylaxis versus rescue with multiple low doses. The French Collaborative Multicentre Study Group.

H Walti1, J Paris-Llado, G Bréart, M Couchard.   

Abstract

The aim of the study was to determine if prophylaxis with multiple low doses of porcine surfactant would increase survival, without bronchopulmonary dysplasia, compared with rescue therapy, for respiratory distress syndrome in newborns of 25-31 weeks' gestation. Compared with rescue therapy (n = 122), prophylaxis (n = 134) decreased the need for oxygenation and ventilatory support within 3-72 h. It did not, however, increase survival without bronchopulmonary dysplasia (60% versus 46%) (odds ratio (OR) = 1.53, 95% confidence interval (CI) = 0.90-2.61). Furthermore, prophylaxis decreased the incidence of severe peri-intraventricular haemorrhage (3% versus 16%) (OR = 0.28, 95% CI = 0.09-0.84) and retinopathy of prematurity (2% versus 11%) (OR = 0.18, CI = 0.04-0.78). We conclude that prophylaxis did not increase survival without bronchopulmonary dysplasia. The decreased incidence of severe peri-intraventricular haemorrhage and retinopathy of prematurity after prophylaxis requires further study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488817     DOI: 10.1111/j.1651-2227.1995.tb13792.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  8 in total

1.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

2.  Appropriate surfactant usage in 1996.

Authors:  R F Soll
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

3.  Systematic review of prophylactic vs rescue surfactant.

Authors:  C J Morley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-07       Impact factor: 5.747

Review 4.  Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.

Authors:  Felicia L Bahadue; Roger Soll
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

5.  Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant ('Curosurf').

Authors:  J Egberts
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

Review 6.  Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.

Authors:  Smeeta Sardesai; Manoj Biniwale; Fiona Wertheimer; Arlene Garingo; Rangasamy Ramanathan
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

7.  Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome.

Authors:  Paola E Cogo; Maddalena Facco; Manuela Simonato; Daniele De Luca; Francesca De Terlizi; Umberto Rizzotti; Giovanna Verlato; Maria Paola Bellagamba; Virgilio P Carnielli
Journal:  Intensive Care Med       Date:  2010-12-10       Impact factor: 17.440

8.  The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.

Authors:  Géraldine Lamboley-Gilmert; Thierry Lacaze-Masmonteil
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.